

Instance: composition-en-703c0707f76711c32684f846cc20b14e
InstanceOf: CompositionUvEpi
Title: "Composition for potactasol Package Leaflet"
Description:  "Composition for potactasol Package Leaflet"
Usage: #inline

* identifier.system = ""

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mock)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - potactasol"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet 
1. What Potactasol is and what it is used for 
2. What you need to know before you use Potactasol 
3. How to use Potactasol 
4. Possible side effects 
5. How to store Potactasol 
6. Contents of the pack and other information </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What potactasol is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What potactasol is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Potactasol contains the active substance topotecan which helps to kill tumour cells.  </p>
<p>Potactasol is used to treat:</p>
<ul>
<li>ovarian cancer or small cell lung cancer that has come back after chemotherapy </li>
<li>advanced cervical cancer if surgery or radiotherapy is not possible. In this case Potactasol 
treatment is combined with medicines containing cisplatin.  </li>
</ul>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take potactasol"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take potactasol"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Potactasol 
- if you are allergic to topotecan or any of the other ingredients of this medicine (listed in 
section 6); 
- if you are breast-feeding.; 
- if your blood cell counts are too low. Your doctor will tell you whether this is the case, based on 
the results of your last blood test. 
Tell you doctor if you think any of these could apply to you. </p>
<p>Warnings and precautions 
Talk to your doctor before using Potactasol:</p>
<ul>
<li>if you have any kidney problems. Your dose of Potactasol may need to be adjusted. Potactasol is 
not recommended in case of severe kidney impairment; </li>
<li>if you have liver problems. Potactasol is not recommended in case of severe liver impairment; </li>
<li>if you suffer from lung inflammation with signs such as cough, fever and difficulties in 
breathing, see also section 4  Possible side effects . </li>
</ul>
<p>Potactasol may cause a decrease in the number of blood clotting cells (platelets). This can lead to 
severe bleeding from relatively small injuries such as a small cut. Rarely, it can lead to more severe 
bleeding (haemorrhage). Talk to your doctor for advice on how to minimize the risk of bleeding. </p>
<p>The incidence of side effects is more frequent in patients who are in poor general health. The doctor 
will evaluate your general health during the treatment and you should tell him/her in case you have 
fever, infection or are in some ways feeling unwell. 
Use in children and adolescents 
The experience in children and adolescents is limited and treatment is therefore not recommended. </p>
<p>Other medicines and Potactasol 
Tell your doctor if you are taking, have recently taken or might take any other medicines. </p>
<p>Pregnancy and breast-feeding 
Potactasol should not be used in pregnant women, unless clearly necessary. If you are or think you 
might be pregnant, tell your doctor immediately. </p>
<p>Effective contraception methods should be used to avoid becoming pregnant or fathering a child while 
on treatment with Potactasol. Ask your doctor for advice. </p>
<p>Patients who are concerned about their fertility should ask their doctor for counselling on fertility and 
family planning options prior to starting treatment. </p>
<p>You must not breast-feed while on treatment with Potactasol.  </p>
<p>Driving and using machines 
Potactasol can make you feel tired or weak. If you experience this, do not drive or use machines. </p>
<p>Potactasol contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per vial, i.e. essentially  sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take potactasol"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take potactasol"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Your dose of Potactasol will depend on:</p>
<ul>
<li>the disease being treated, </li>
<li>your body surface area (m2), </li>
<li>the results of blood tests carried out before and during treatment, </li>
<li>how well you tolerate treatment. </li>
</ul>
<p>Adults 
Ovarian cancer and small cell lung cancer 
The usual dose is 1.5 mg per m2 of body surface area once daily for 5 days. This treatment cycle will 
normally be repeated every three weeks. </p>
<p>Cervical cancer 
The usual dose is 0.75 mg per m2 of body surface area once daily for 3 days. This treatment cycle will 
normally be repeated every three weeks. 
For cervical cancer, it will be used together with another anticancer medicines containing cisplatin. 
For more information about cisplatin, please refer to the corresponding package leaflet. </p>
<p>Patients with impaired kidney function 
Your doctor might need to reduce your dose based on your kidney function. </p>
<p>How Potactasol is prepared 
Topotecan is supplied as a powder for concentrate for solution for infusion. The powder must be 
dissolved, and the resulting concentrate further diluted before administration. </p>
<p>How Potactasol is given 
A doctor or nurse will give you the reconstituted and diluted Potactasol solution as an infusion (drip), 
usually into your arm, over about 30 minutes. </p>
<p>If you are given too much Potactasol 
As this medicine is being given by your doctor or nurse, it is unlikely that you will be given too much. 
In the unlikely event of an overdose, your doctor will monitor you for side effects. Tell your doctor or 
nurse if you have any concerns about the amount of medicine that you receive. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Serious side effects 
You must tell your doctor immediately if you experience any of the following serious side effects. 
They may require hospitalisation and could even be life-threatening. </p>
<ul>
<li>
<p>Infections (very common; may affect more than 1 in 10 people), with signs such as:</p>
</li>
<li>
<p>fever </p>
</li>
<li>serious decline of your general condition </li>
<li>local symptoms, such as sore throat or burning sensation when urinating </li>
<li>
<p>severe stomach pain, fever and possibly diarrhoea (rarely with blood) can be signs of bowel 
inflammation (neutropenic colitis) 
Potactasol may reduce your ability to fight infections. </p>
</li>
<li>
<p>Lung inflammation (rare; may affect up to 1 in 1,000 people), with signs such as:</p>
</li>
<li>
<p>difficulty breathing </p>
</li>
<li>cough </li>
<li>
<p>fever 
The risk of developing this severe condition (interstitial lung disease) is higher if you currently have 
lung problems, or if you have received previous radiation treatment or medicines that affected your 
lungs, see also section 2  Warnings and precautions . This condition can be fatal. </p>
</li>
<li>
<p>Severe allergic (anaphylactic) reactions (rare; may affect up to 1 in 1,000 people), with signs 
such as:</p>
</li>
<li>
<p>swelling of the face, lips, tongue or throat, difficulty breathing, low blood pressure, dizziness 
and itchy rash. </p>
</li>
</ul>
<p>Other side effects with Potactasol include: </p>
<p>Very common side effects (may affect more than 1 in 10 people) 
- Feeling generally weak and tired, which can be symptoms of a decrease in the number of red 
blood cells (anaemia). In some cases you may need a blood transfusion. 
- Decrese in number of circulating white blood cells (leucotyes) in the blood. Abnormal low 
number of neutrophil granulocytes (a type of white blood cell) in the blood, with or without 
fever. 
- Unusual bruising or bleeding, sometimes severe, caused by a decrease in the number of blood 
clotting cells (platelets). 
- Weight loss and loss of appetite (anorexia); tiredness; weakness. 
- Feeling sick (nausea), vomiting; diarrhoea; stomach pain; constipation. 
- Inflammation of the lining of the mouth and digestive tract. 
- Fever. 
- Hair loss. </p>
<p>Common side effects (may affect up to 1 in 10 people) 
- Allergic (hypersensitivity) reactions (including rash). 
- Abnormal high level of bilirubin, a waste product produced by the liver during breakdown of 
red blood cells. Symptoms may include yellow skin (jaundice). 
- Decrease in the number of all blood cells (pancytopenia). 
- Feeling unwell. 
- Serious blood infection, which can be fatal. 
- Itching (pruritus). </p>
<p>Rare side effects (may affect up to 1 in 1,000 people) 
- Swelling caused by fluid build-up (angioedema) e.g. around the eyes and lips as well as hands, 
feet and throat. If severe it may cause breathing difficulties. 
- Itchy rash (or hives). </p>
<p>Very rare side effects (may affect up to 1 in 10,000 people) 
- Mild pain and inflammation at the site of injection due to accidental administration of the 
medicinal product into the surrounding tissue (extravasation) e.g. by leakage. </p>
<p>Not known (frequency cannot be estimated from the available data) 
- Severe stomach pain, nausea, vomiting of blood, black or bloody stools (possible symptoms of 
gastrointestinal perforation). 
- Mouth sores, difficulty swallowing, abdominal pain, nausea, vomiting, diarrhoea, bloody stools 
(possible signs and symptoms of inflammation of the inner lining of the mouth, stomach and/or 
gut [mucosal inflammation]). </p>
<p>If you are being treated for cervical cancer, you may get side effects from the other medicine 
(cisplatin) that you will be given along with Potactasol.  </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not 
listed in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. By reporting side effects you can help provide more information on the safety of this 
medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store potactasol"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store potactasol"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the vial and carton after EXP. The 
expiry date refers to the last day of that month. </p>
<p>Keep the vial in the outer carton in order to protect from light. </p>
<p>Storage after reconstitution and dilution 
Chemical and physical stability of the concentrate has been demonstrated for 24 hours at 25   2 C, in 
normal light conditions and 24 hours at 2 C to 8 C, protected from light. </p>
<p>The physico-chemical stability of the medicinal product solution obtained after dilution in solutions 
for infusion (NaCl 0.9 % and Glucose 5 %) has been demonstrated for 4 hours at room temperature, in 
normal lighting conditions, on samples reconstituted and stored for 12 hours and respectively 24 hours 
at 25oC   2oC and then diluted. </p>
<p>From a microbiological point of view, the product should be used immediately. If not used 
immediately, in-use storage times and conditions prior to use are the responsibility of the user and 
would normally not be longer than 24 hours at 2 C to 8 C, unless reconstitution/dilution has taken 
place in controlled and validated aseptic conditions. </p>
<p>Any unused product or waste material should be disposed of in accordance with local requirements for 
cytotoxic material. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Potactasol contains 
- The active substance is topotecan. Each vial contains 1 mg or 4 mg topotecan (as 
hydrochloride). After reconstitution 1 ml concentrate contains 1 mg topotecan.<br />
- The other ingredients are: mannitol (E421), tartaric acid (E334), hydrochloric acid (E507) and 
sodium hydroxide (see section 2). </p>
<p>What Potactasol looks like and contents of the pack 
Potactasol is supplied in type I colourless glass vials with grey bromobutylic stopper and aluminium 
seals with plastic flip-off caps. Vials may or may not be sheathed in a protective sleeve. Vials contain 
either 1 mg or 4 mg of topotecan. </p>
<p>Each pack contains one vial. </p>
<p>Marketing Authorisation Holder<br />
Actavis Group PTC ehf. 
Dalshraun 1 
220 Hafnarfj r ur 
Iceland </p>
<p>Manufacturer 
S.C. Sindan-Pharma S.R.L. 
11 Ion Mihalache Blvd 
Bucharest 
Romania </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Teva Pharma Belgium N.V./S.A./AG 
T l/Tel: +32 38207Lietuva 
UAB Teva Baltics 
Tel: +370 52660  </p>
<p>Te : +359 24899Luxembourg/Luxemburg 
Teva Pharma Belgium N.V./S.A./AG 
Belgique/Belgien 
T l/Tel: +32 38207 esk  republika 
Teva Pharmaceuticals CR, s.r.o. 
Tel: +420 251007Magyarorsz g 
Teva Gy gyszergy r Zrt. 
Tel: +36 12886Danmark 
Teva Denmark A/S 
Tlf: +45 44985Malta 
Teva Pharmaceuticals Ireland 
L-Irlanda 
Tel: +44 2075407Deutschland 
ratiopharm GmbH 
Tel: +49 73140Nederland 
Teva Nederland B.V. 
Tel: +31 8000228Eesti 
UAB Teva Baltics Eesti filiaal 
Tel: +372 6610Norge 
Teva Norway AS 
Tlf: +47 66775<br />
Specifar A.B.E.E. 
 : +30 2118805 sterreich 
ratiopharm Arzneimittel Vertriebs-GmbH 
Tel: +43 1970Espa a 
Teva Pharma, S.L.U. 
Tel: +34 913873Polska 
Teva Pharmaceuticals Polska Sp. z o.o. 
Tel: +48 223459France 
Teva Sant<br />
T l: +33 155917Portugal 
Teva Pharma - Produtos Farmac uticos, Lda. 
Tel: +351 214767Hrvatska 
Pliva Hrvatska d.o.o.<br />
Tel: +385 13720Rom nia 
Teva Pharmaceuticals S.R.L. 
Tel: +40 212306Ireland 
Teva Pharmaceuticals Ireland 
Tel: +44 2075407Slovenija 
Pliva Ljubljana d.o.o. 
Tel: +386 15890 sland 
Teva Pharma Iceland ehf. 
S mi: +354 5503Slovensk  republika 
TEVA Pharmaceuticals Slovakia s.r.o. 
Tel: +421 257267Italia 
Teva Italia S.r.l. 
Tel: +39 028917Suomi/Finland 
Teva Finland Oy 
Puh/Tel: +358 201805<br />
Specifar A.B.E.E.  </p>
<p>: +30 2118805Sverige 
Teva Sweden AB 
Tel: +46 42121Latvija 
UAB Teva Baltics fili le Latvij <br />
Tel: +371 67323United Kingdom (Northern Ireland) 
Teva Pharmaceuticals Ireland 
Ireland 
Tel: +44 2075407This leaflet was last revised in {MM/YYYY}. </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      

